<DOC>
	<DOCNO>NCT02615704</DOCNO>
	<brief_summary>An electronic device application ( APP ) `` Mein Herz und ich '' develop specifically acute coronary syndrome ( ACS ) patient prescribe Brilique ( ticagrelor ) increase adherence treatment ( medication lifestyle change ) combination reminder medication intake , information importance treatment , motivation supportive message , visualisation individual lifestyle choice ' effect cardiovascular risk . The aim study evaluate effectiveness patient support tool .</brief_summary>
	<brief_title>`` Me My Heart '' Study</brief_title>
	<detailed_description>The target population patient hospitalise acute coronary syndrome ( ACS ) 18 year old access electronic device ( compatible patient support tool ) , diagnose ST elevation myocardial infarction ( STEMI ) , non-ST elevation myocardial infarction ( NSTEMI ) , unstable angina pectoris ( UA ) treat twice daily Brilique ( ticagrelor ) co administer low dose acetylsalicylic acid ( ASA ) accord prescription recommendation , within 14 day follow diagnosis ACS event . Patients randomise 1:1 active group receive patient support tool investigation via electronic device application ( APP ) control group without patient support tool . In addition , active control group randomise 1:1 group without use Medical Event Monitoring System ( MEMS ) evaluation treatment adherence . Patient questionnaire evaluation lifestyle change , quality life administer begin ( Visit 1 ) end ( Visit 2 ) observation period . In addition , questionnaires adherence , treatment attitude , health care utilization risk factor administer monthly interval . This randomised investigation accord paragraph 23b German Medical Device Law examine impact APP use drug adherence , drug persistence lifestyle change patient prescribed Brilique ( ticagrelor ) part normal clinical practice 12 month timeframe ACS episode . The device European Conformity Declaration ( CE-mark ) . In study investigational product dispense study participant . Patients need provide Brilique ( ticagrelor ) supply pharmacy , common clinical practice . Further , assessment study use guide treatment patient participate study .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision sign dated patient inform consent prior randomisation Female male age 18 year old Acute Coronary Syndrome patient , diagnose ST elevation myocardial infarction , nonST elevation myocardial infarction unstable angina pectoris treat Brilique ( ticagrelor ) prior inclusion study treat physician intend continue prescribe twice daily Brilique ( ticagrelor ) co administer low dose acetylsalicylic acid accord prescription recommendation , within 14 day follow diagnosis ACS event Ability read , understand write German Patients must access electronic device ( compatible patient support tool ) willing use daily basis Involvement planning and/or conduct study ( applies AstraZeneca staff and/or staff study site application developer ) Participation another clinical study investigational product medical device last 30 day , exclude prospective/retrospective register base study require extra visit addition ordinary health care Patients treatment Oral AntiPlatelet drug Brilique ( ticagrelor ) Patients contraindication use Brilique ( ticagrelor ) Patients accepted/with plan thoracic surgery ( coronary artery bypass grafting , CABG ) elective surgery postpone study participation Presence serious/severe comorbidities opinion Investigator may limit life expectancy ( &lt; 1 year ) For woman : patient currently pregnant ( confirm positive pregnancy test ) breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Brilique treatment adherence via electronic device application ( APP )</keyword>
</DOC>